Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design
- 2 May 2000
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 34 (2) , 83-88
- https://doi.org/10.1016/s1040-8428(00)00055-x
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilonesProceedings of the National Academy of Sciences, 1998
- Matrix metalloproteinase inhibitors: Present achievements and future prospectsInvestigational New Drugs, 1997
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic miceNature Medicine, 1995